CY1115517T1 - Νεα παρεντερικη συνταγοποιηση καρβαμαζεπινης - Google Patents
Νεα παρεντερικη συνταγοποιηση καρβαμαζεπινηςInfo
- Publication number
- CY1115517T1 CY1115517T1 CY20141100467T CY141100467T CY1115517T1 CY 1115517 T1 CY1115517 T1 CY 1115517T1 CY 20141100467 T CY20141100467 T CY 20141100467T CY 141100467 T CY141100467 T CY 141100467T CY 1115517 T1 CY1115517 T1 CY 1115517T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carbamazepine
- cyclodextrin
- cyclodextrins
- karvamazepin
- coparagraph
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 abstract 5
- 229940097362 cyclodextrins Drugs 0.000 abstract 3
- 239000012530 fluid Substances 0.000 abstract 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 abstract 2
- 229960000623 carbamazepine Drugs 0.000 abstract 2
- 238000007911 parenteral administration Methods 0.000 abstract 2
- 125000004964 sulfoalkyl group Chemical group 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000008156 Ringer's lactate solution Substances 0.000 abstract 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000002504 physiological saline solution Substances 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72269205P | 2005-09-30 | 2005-09-30 | |
| EP06816054.8A EP1928464B1 (en) | 2005-09-30 | 2006-10-02 | Novel parenteral carbamazepine formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115517T1 true CY1115517T1 (el) | 2017-01-04 |
Family
ID=37906812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100467T CY1115517T1 (el) | 2005-09-30 | 2014-06-26 | Νεα παρεντερικη συνταγοποιηση καρβαμαζεπινης |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20070185054A1 (enExample) |
| EP (2) | EP1928464B1 (enExample) |
| JP (2) | JP5284096B2 (enExample) |
| CN (1) | CN101309691A (enExample) |
| AU (1) | AU2006299501B2 (enExample) |
| BR (1) | BRPI0616447A2 (enExample) |
| CA (1) | CA2624463C (enExample) |
| CY (1) | CY1115517T1 (enExample) |
| DK (1) | DK1928464T3 (enExample) |
| ES (2) | ES2475157T3 (enExample) |
| MX (1) | MX2008004287A (enExample) |
| NZ (1) | NZ567290A (enExample) |
| PL (1) | PL1928464T3 (enExample) |
| PT (1) | PT1928464E (enExample) |
| RU (2) | RU2455996C2 (enExample) |
| SI (1) | SI1928464T1 (enExample) |
| WO (1) | WO2007041524A2 (enExample) |
| ZA (1) | ZA200803332B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| RU2464042C1 (ru) * | 2011-03-31 | 2012-10-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО |
| US20140178479A1 (en) | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| US11235020B2 (en) * | 2013-03-13 | 2022-02-01 | Abraham Palmer | Methods and compositions for inhibiting glyoxalase 1 (GLO1) |
| CN105726466A (zh) * | 2014-12-10 | 2016-07-06 | 辽宁药联制药有限公司 | 一种奥卡西平注射剂及其制备方法 |
| MY200159A (en) * | 2016-12-14 | 2023-12-09 | Sk Biopharmaceuticals Co Ltd | Parenteral liquid preparation comprising carbamate compound |
| WO2020157257A1 (en) * | 2019-02-01 | 2020-08-06 | H. Lundbeck A/S | Injectable carbamazepine composition essentially free of 10-br-carbamazepine |
| US12383633B1 (en) | 2024-10-01 | 2025-08-12 | Zymeron Corporation | Injectable formulations of PARP inhibitors and uses thereof |
| CN120754274A (zh) * | 2025-07-15 | 2025-10-10 | 江苏鹏鹞药业有限公司 | 一种卡马西平的生产工艺及负载分散剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US5231098A (en) * | 1987-06-26 | 1993-07-27 | Nihon Bayer Agrochem K.K. | Insecticidal nitro-substituted heterocyclic compounds |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US6546131B1 (en) | 1990-12-19 | 2003-04-08 | Canon Kabushiki Kaisha | Image processing method and apparatus for achieving tone reproduction suited to the image |
| US5231089A (en) * | 1991-12-02 | 1993-07-27 | University Of Florida | Method of improving oral bioavailability of carbamazepine |
| FR2713934B1 (fr) | 1993-12-22 | 1996-01-12 | Commissariat Energie Atomique | Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives. |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| US6046177A (en) * | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| GB9721497D0 (en) | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
| AU772204B2 (en) | 1999-01-21 | 2004-04-22 | Bristol-Myers Squibb Company | Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method |
| KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
| JP2006509788A (ja) | 2002-11-27 | 2006-03-23 | ファルマシア・コーポレーション | バルデコキシブの濃縮液体組成物 |
-
2006
- 2006-10-02 WO PCT/US2006/038508 patent/WO2007041524A2/en not_active Ceased
- 2006-10-02 ES ES06816054.8T patent/ES2475157T3/es active Active
- 2006-10-02 CA CA2624463A patent/CA2624463C/en active Active
- 2006-10-02 MX MX2008004287A patent/MX2008004287A/es active IP Right Grant
- 2006-10-02 SI SI200631794T patent/SI1928464T1/sl unknown
- 2006-10-02 ES ES12150783T patent/ES2708375T3/es active Active
- 2006-10-02 EP EP06816054.8A patent/EP1928464B1/en not_active Revoked
- 2006-10-02 PT PT68160548T patent/PT1928464E/pt unknown
- 2006-10-02 EP EP12150783.4A patent/EP2444090B1/en active Active
- 2006-10-02 DK DK06816054.8T patent/DK1928464T3/da active
- 2006-10-02 RU RU2008117161/15A patent/RU2455996C2/ru not_active IP Right Cessation
- 2006-10-02 JP JP2008533754A patent/JP5284096B2/ja not_active Expired - Fee Related
- 2006-10-02 AU AU2006299501A patent/AU2006299501B2/en not_active Ceased
- 2006-10-02 NZ NZ567290A patent/NZ567290A/en not_active IP Right Cessation
- 2006-10-02 BR BRPI0616447-1A patent/BRPI0616447A2/pt not_active IP Right Cessation
- 2006-10-02 US US11/542,520 patent/US20070185054A1/en not_active Abandoned
- 2006-10-02 PL PL06816054T patent/PL1928464T3/pl unknown
- 2006-10-02 CN CNA2006800428107A patent/CN101309691A/zh active Pending
-
2008
- 2008-04-15 ZA ZA2008/03332A patent/ZA200803332B/en unknown
-
2012
- 2012-04-02 RU RU2012112839/15A patent/RU2012112839A/ru not_active Application Discontinuation
- 2012-10-17 JP JP2012230330A patent/JP5794966B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-26 CY CY20141100467T patent/CY1115517T1/el unknown
-
2021
- 2021-10-14 US US17/501,287 patent/US20220265547A1/en not_active Abandoned
-
2023
- 2023-06-16 US US18/336,419 patent/US20240165125A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5794966B2 (ja) | 2015-10-14 |
| ES2708375T3 (es) | 2019-04-09 |
| WO2007041524A3 (en) | 2007-09-13 |
| EP1928464B1 (en) | 2014-05-14 |
| CA2624463A1 (en) | 2007-04-12 |
| AU2006299501A1 (en) | 2007-04-12 |
| US20070185054A1 (en) | 2007-08-09 |
| JP2013040195A (ja) | 2013-02-28 |
| DK1928464T3 (da) | 2014-06-23 |
| AU2006299501A2 (en) | 2008-05-08 |
| ZA200803332B (en) | 2011-05-25 |
| EP2444090A1 (en) | 2012-04-25 |
| US20220265547A1 (en) | 2022-08-25 |
| RU2012112839A (ru) | 2013-10-10 |
| WO2007041524A2 (en) | 2007-04-12 |
| JP5284096B2 (ja) | 2013-09-11 |
| RU2455996C2 (ru) | 2012-07-20 |
| US20240165125A1 (en) | 2024-05-23 |
| ES2475157T3 (es) | 2014-07-10 |
| EP1928464A2 (en) | 2008-06-11 |
| RU2008117161A (ru) | 2009-11-10 |
| SI1928464T1 (sl) | 2014-09-30 |
| NZ567290A (en) | 2011-08-26 |
| BRPI0616447A2 (pt) | 2011-06-21 |
| AU2006299501B2 (en) | 2012-11-29 |
| CA2624463C (en) | 2017-02-14 |
| PL1928464T3 (pl) | 2014-10-31 |
| EP2444090B1 (en) | 2018-12-12 |
| JP2009510123A (ja) | 2009-03-12 |
| MX2008004287A (es) | 2008-10-23 |
| PT1928464E (pt) | 2014-07-10 |
| EP1928464A4 (en) | 2009-10-21 |
| CN101309691A (zh) | 2008-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | An approach to developing cyanines with simultaneous intersystem crossing enhancement and excited-state lifetime elongation for photodynamic antitumor metastasis | |
| Hannah et al. | DNA-templated assembly of helical cyanine dye aggregates: a supramolecular chain polymerization | |
| Pantos et al. | Filling helical nanotubes with C60 | |
| Ye et al. | Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors | |
| Renikuntla et al. | Improved photostability and fluorescence properties through polyfluorination of a cyanine dye | |
| Uddin et al. | Design, synthesis, and structure–activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents | |
| Chen et al. | NIR-II fluorescence imaging for in vivo quantitative analysis | |
| CY1110853T1 (el) | Πεγκυλιωμενες ενωσεις glp-1 | |
| Dwyer et al. | Chemoenzymatic sensitization of DNA photonic wires mediated through quantum dot energy transfer relays | |
| Lehrman et al. | Supramolecular control of self-assembling terthiophene–peptide conjugates through the amino acid side chain | |
| CY1114992T1 (el) | Μονοδιεσπαρμενες πεγκυλιωμενες συνθεσεις ναλοξολης | |
| ES2179196T3 (es) | Complejos radiofarmacos ternarios. | |
| CY1105131T1 (el) | Ενδορρινικος σχηματισμος ροτιγκοτινης | |
| ATE409209T1 (de) | Hydrophile, thiolreaktive cyaninfarbstoffe und deren konjugate mit biomolekülen für fluoreszenzdiagnose | |
| CY1105962T1 (el) | Υποκατεστημενα παραγωγα διοξειδιου θειαζολο-βενζοϊσοθειαζολιου, μεθοδος για την παραγωγη αυτων και η χρηση αυτων | |
| CY1109593T1 (el) | Παραγωγα 12,13-κυκλοπροπανο εποθιλονης | |
| CY1114198T1 (el) | Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη | |
| ATE304709T1 (de) | Substanzen mit verzweigten linkermolekülen | |
| ATE304866T1 (de) | Chelatorkonjugate mit verbesserten eigenschaften | |
| 서형필 et al. | Production of $\beta $-1, 3/1, 6-glucan by Aureobasidium pullulans SM-2001 | |
| FR3098912B1 (fr) | Capteurs fluorescents à base de nanomatériaux et méthodes connexes | |
| Shen et al. | Trigonal nitrogen activates high-brightness chemiluminescent carbon nanodots | |
| WO2007041524A3 (en) | Novel parenteral carbamazepine formulation | |
| CY1106331T1 (el) | Κλειστο συμπλοκο της ταξολης με 2-υδροξυπροπυλ-βητα-κυκλοδεξτρινη | |
| Kang et al. | Porphyrin–Peptoid conjugates: face-to-face display of porphyrins on peptoid helices |